Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLB101 vs Blincyto in Adult R/R CD19+ B-ALL
NCT07723911Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2026
- Primary completion
- Oct 2027
01
Overview
A Phase 3 trial of BLB-101 in B-cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
BLB-101
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07723911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07723911.